B cell lymphoma in hiv transgenic mice

Retrovirology

Joseph Bryant⁴  Robert C Gallo¹  Davide Zella³  Alfredo Garzino-Demo²  Mark K Lafferty²  Yanto Lunardi-Iskandar⁴  Marvin Reitz⁴  Selvi Krishnan⁴  Sabrina Curreli⁴ 

[1] Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA;Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA;Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA;Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA

关键词: Transgenic mice;    HIV-1;    B lymphoma;   

Others  :  1209068
DOI  :  10.1186/1742-4690-10-92

 received in 2013-06-04, accepted in 2013-08-22,  发布年份 2013

【 摘 要 】

Background

Human Immunodeficiency Virus Type I (HIV-1) infection is associated with a high incidence of B-cell lymphomas. The role of HIV in these lymphomas is unclear and currently there are no valid in vivo models for better understanding HIV-related lymphomagenesis. Transgenic (Tg) 26 mice have a 7.4-kb pNL4-3 HIV-1 provirus lacking a 3.1-kb sequence encompassing parts of the gag-pol region. Approximately 15% of these HIV Tg mice spontaneously develop lymphoma with hallmark pre-diagnostic markers including skin lesions, diffuse lymphadenopathy and an increase in pro-inflammatory serum cytokines. Here we describe the phenotypic and molecular characteristics of the B cell leukemia/lymphoma in the Tg mice.

Results

The transformed B cell population consists of CD19⁺pre-BCR⁺CD127⁺CD43⁺CD93⁺ precursor B cells. The tumor cells are clonal and characterized by an increased expression of several cellular oncogenes. Expression of B cell-stimulatory cytokines IL-1β, IL-6, IL-10, IL-12_p40, IL-13 and TNFα and HIV proteins p17, gp120 and nef were elevated in the Tg mice with lymphoma.

Conclusions

Increased expression of HIV proteins and the B-cell stimulatory factors is consistent with the interpretation that one or more of these factors play a role in lymphoma development. The lymphomas share many similarities with those occurring in HIV/AIDS⁺ patients and may provide a valuable model for understanding AIDS-related lymphomagenesis and elucidating the role played by HIV-1.

【 授权许可】

   
2013 Curreli et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Grogg KL, Miller RF, Dogan A: HIV infection and lymphoma. J Clin Pathol 2007, 60:1365-1372.
• [2]Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, Katlama C, Charlotte F, Dupont B, Brousse N, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001, 98:2339-2344.
• [3]Epeldegui M, Widney DP, Martinez-Maza O: Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 2006, 18:444-448.
• [4]Pelicci PG, Knowles DM 2nd, Arlin ZA, Wieczorek R, Luciw P, Dina D, Basilico C, Dalla-Favera R: Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med 1986, 164:2049-2060.
• [5]Przybylski GK, Goldman J, Ng VL, McGrath MS, Herndier BG, Schenkein DP, Monroe JG, Silberstein LE: Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood 1996, 88:4620-4629.
• [6]Martinez-Maza O, Breen EC: B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002, 14:528-532.
• [7]Vendrame E, Martinez-Maza O: Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res 2011, 10:113-119.
• [8]Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martinez-Maza O: Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999, 93:114-123.
• [9]Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martinez-Maza O: Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006, 27:187-194.
• [10]He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, Moore JP, Cerutti A: HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006, 176:3931-3941.
• [11]Lefevre EA, Krzysiek R, Loret EP, Galanaud P, Richard Y: Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. J Immunol 1999, 163:1119-1122.
• [12]Epeldegui M, Thapa DR, De la Cruz J, Kitchen S, Zack JA, Martinez-Maza O: CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One 2010, 5:e11448.
• [13]van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, Niesters HG, Osterhaus AD, McMichael AJ, van Oers MH, Miedema F: Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001, 98:146-155.
• [14]Carbone A, Gloghini A: KSHV/HHV8-associated lymphomas. Br J Haematol 2008, 140:13-24.
• [15]Leonard JM, Abramczuk JW, Pezen DS, Rutledge R, Belcher JH, Hakim F, Shearer G, Lamperth L, Travis W, Fredrickson T, et al.: Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science 1988, 242:1665-1670.
• [16]Feinberg MB, Moore JP: AIDS vaccine models: challenging challenge viruses. Nat Med 2002, 8:207-210.
• [17]Tinkle BT, Ueda H, Ngo L, Luciw PA, Shaw K, Rosen CA, Jay G: Transgenic dissection of HIV genes involved in lymphoid depletion. J Clin Invest 1997, 100:32-39.
• [18]Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, Jolicoeur P: Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol 1998, 72:121-132.
• [19]van Maanen M, Sutton RE: Rodent models for HIV-1 infection and disease. Current HIV research 2003, 1:121-130.
• [20]Dickie P, Felser J, Eckhaus M, Bryant J, Silver J, Marinos N, Notkins AL: HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991, 185:109-119.
• [21]Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, Eckhaus M, Bryant JL, Notkins AL, Klotman PE: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 1992, 89:1577-1581.
• [22]Kopp JB, Rooney JF, Wohlenberg C, Dorfman N, Marinos NJ, Bryant JL, Katz SI, Notkins AL, Klotman PE: Cutaneous disorders and viral gene expression in HIV-1 transgenic mice. AIDS Res Hum Retroviruses 1993, 9:267-275.
• [23]Santoro TJ, Bryant JL, Pellicoro J, Klotman ME, Kopp JB, Bruggeman LA, Franks RR, Notkins AL, Klotman PE: Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. Virology 1994, 201:147-151.
• [24]Stoltzfus CM: Regulation of HIV-1 alternative RNA splicing and its role in virus replication. Adv Virus Res 2009, 74:1-40.
• [25]Giagulli C, Marsico S, Magiera AK, Bruno R, Caccuri F, Barone I, Fiorentini S, Ando S, Caruso A: Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 2011, 6:e17831.
• [26]Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M: HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424:213-219.
• [27]Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, Chmiel JS, Rinaldo CR, Lai S, Martinez-Maza O: Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter −592 C/C genotype. Clin Immunol 2003, 109:119-129.
• [28]Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, Reding DJ, Rothman N: Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 2011, 71:4898-4907.
• [29]Hardy RR, Hayakawa K: B cell development pathways. Annu Rev Immunol 2001, 19:595-621.
• [30]Kawamoto H, Ikawa T, Ohmura K, Fujimoto S, Katsura Y: T cell progenitors emerge earlier than B cell progenitors in the murine fetal liver. Immunity 2000, 12:441-450.
• [31]Rui L, Schmitz R, Ceribelli M, Staudt LM: Malignant pirates of the immune system. Nat Immunol 2011, 12:933-940.
• [32]Klapproth K, Wirth T: Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010, 149:484-497.
• [33]Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A: Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007, 104:3207-3212.
• [34]Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, et al.: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012, 109:3879-3884.
• [35]Rosenberg N, Witte ON: The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res 1988, 35:39-81.
• [36]Shore SK, Tantravahi RV, Reddy EP: Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene 2002, 21:8568-8576.
• [37]Hartley JW, Evans LH, Green KY, Naghashfar Z, Macias AR, Zerfas PM, Ward JM: Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line. Retrovirology 2008, 5:1. BioMed Central Full Text
• [38]Popovic M: Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 1995, 102(41):14807-14812.
• [39]Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR: Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001, 167:6834-6840.
• [40]Kondo M, Weissman IL, Akashi K: Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997, 91(5):661-672.
• [41]Herzog S, Reth M, Jumaa H: Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 2009, 9:195-205.
• [42]Ochiai K, Maienschein-Cline M, Mandal M, Triggs JR, Bertolino E, Sciammas R, Dinner AR, Clark MR, Singh H: A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat Immunol 2012, 13:300-307.
• [43]Perez-Vera P, Reyes-Leon A, Fuentes-Panana EM: Signaling proteins and transcription factors in normal and malignant early B cell development. Bone Marrow Res 2011, 2011:502751.
• [44]Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr 2010, 54:18-26.
• [45]Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
• [46]Teitell MA, Pandolfi PP: Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol 2009, 4:175-198.
• [47]Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R: Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993, 81:166-176.
• [48]Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, Gold J, Finlayson RJ, Cooper DA, Kaldor JM: B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000, 14:133-140.
• [49]Kozak CA: The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology 2010, 7:101. BioMed Central Full Text
• [50]Wong R, Balachandran A, Mao AY, Dobson W, Gray-Owen S, Cochrane A: Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy. Retrovirology 2011, 8:47. BioMed Central Full Text